FDA On Track With MDUFMA Review Goals, Report Shows
This article was originally published in The Gray Sheet
Executive Summary
FDA is on course to meet its 2005 and 2006 review performance goals under the Medical Device User Fee & Modernization Act (MDUFMA), according to a report released by the agency last week
You may also be interested in...
Industry Favors Predictability Over Speed In Next Round Of MDUFMA
Senior device industry staffers are more interested in improving the predictability of FDA's premarket review process than pushing the agency to accelerate its performance, an FDA 1report suggests
Funding Limits Will Force Choices At Device Evaluation Office – Tillman
FDA's device center says it will meet its fiscal year 2006 submission review time performance goals, but other activities might be neglected, given anticipated revenue
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.